Lungs

These ingredients are often used in alternative medicine to support lungs.

• ajwainScientific

  Direct human clinical evidence exists for ajwain's bronchodilatory effect in asthmatic patients (Boskabady 2007, Therapie). Antitussive and tracheal smooth muscle relaxant effects are documented in animal models. Thymol is a recognized pharmaceutical bronchodilatory constituent.

• alpha-caroteneScientific

  Prospective epidemiological studies show high serum alpha-carotene significantly associated with lower lung cancer mortality, distinct from the null or harmful effects of supplemental beta-carotene in smokers. A 2014 NHANES III study (N=10,382; 161 lung cancer deaths) identified high serum alpha-carotene as one of only two carotenoids significantly protective against lung cancer death. A Japanese JACC nested case-control found alpha-carotene's highest quartile associated with OR=0.41 for lung cancer death in men.

• andrographisScientific

  Andrographis (Andrographis paniculata) has been used for centuries in Indian and Chinese traditional medicine for cough, cold, and respiratory infections. Its active compound andrographolide inhibits bacterial adhesion to lung epithelium, exerts antiviral activity against influenza, and reduces airway inflammation. A PLOS ONE systematic review and meta-analysis of RCTs confirmed it shortened cough duration and accelerated resolution of acute respiratory tract infections.

• andrographolideScientific

  Andrographolide is the primary active diterpene lactone from Andrographis paniculata, with documented direct mechanisms for lung protection. It inhibits bacterial adhesion to lung epithelial cells, blocks influenza A viral replication, reduces PM2.5-induced lung injury, and inhibits NLRP3 inflammasome reducing pulmonary inflammation and fibrosis. In vitro and animal studies confirm specific activity against silicosis and pulmonary fibrosis models.

• anemarrhena asphodeloidesScientific

  Timosaponin AIII from anemarrhena significantly reduced LPS-induced acute lung inflammation in mice, with histological evidence of reduced alveolar damage and inflammatory infiltration. Traditional classification as a Lung-system herb with moistening and heat-clearing actions underpins 2,000 years of respiratory use.

• aniseScientific

  Anise has official monograph recognition (ESCOP, EMA) for expectorant and secretolytic actions on the lungs and airways. A cell-line study confirmed aniseed essential oil reduces pro-inflammatory cytokines and stimulates protective mucus secretion in bronchial epithelial cells. Animal studies show bronchodilatory effects on lung airways.

• annattoScientific

  Bixin-loaded nanoparticles have demonstrated protection against cigarette smoke-induced acute lung inflammation and oxidative stress in animal models. Preclinical studies show bixin reduces pulmonary NF-κB activation and cytokine-driven inflammation. Traditional use of annatto leaves as a respiratory treatment for bronchitis and pulmonary disorders is also documented.

• appleScientific

  Apple consumption is associated with better lung function and reduced asthma risk in epidemiological studies. Apple quercetin relaxes airway smooth muscle via PDE4 inhibition, and procyanidin-rich apple extracts suppress allergic airway inflammation in cell and animal models.

• astaxanthinScientific

  Astaxanthin is a marine carotenoid with potent antioxidant activity documented to protect lung tissue from oxidative stress. Preclinical studies demonstrate it reduces lung inflammation, oxidative damage, and fibrosis in animal models of COPD, acute lung injury, and PM2.5-induced pulmonary toxicity. Clinical research is limited but suggests benefit in respiratory conditions associated with oxidative stress.

• aster rootScientific

  The lungs are the primary target organ of Aster root in both TCM theory and modern pharmacology. Preclinical studies confirm protection against acute lung injury, suppression of pulmonary inflammatory cytokines, reduction of pulmonary edema, and expectorant/antitussive activity in lung-related models. The Chinese Pharmacopoeia includes it for lung moistening and phlegm elimination.

• astragalusScientific

  Astragalus (Astragalus membranaceus) is a foundational herb in TCM for tonifying lung qi. Modern research confirms immunomodulatory, anti-inflammatory, and antifibrotic activity in the lung. Clinical evidence includes use in preventing upper respiratory tract infections in children with nephrotic syndrome (PMC3638577 RCT evidence review) and in integrative oncology for lung conditions. Astragaloside IV has demonstrated lung protective effects against fibrosis and inflammation.

• baikal skullcapScientific

  The lungs are a primary organ target for S. baicalensis, supported by clinical use in China for viral pneumonia, bronchial asthma, and upper respiratory infections, as well as preclinical evidence of baicalin reducing viral lung injury and inflammatory cell infiltration in RSV mouse models.

• basilScientific

  A BMC Complementary Medicine (2019) animal RCT confirmed O. basilicum reduced lung pathological changes in asthma. A Frontiers in Pharmacology systematic review (2021) covers experimental and preclinical lung evidence for COPD, asthma, bronchitis, and aspergillosis. Linalool metabolites have demonstrated bronchodilatory properties.

• belleric myrobalanScientific

  Pharmacological evidence confirms T. bellirica exerts bronchodilatory effects on lung airways via anticholinergic and calcium channel antagonist mechanisms. Traditional use for asthma, bronchitis, and phlegm is extensively documented. The fruit's antimicrobial activity against respiratory pathogens (S. pneumoniae) and anti-inflammatory effects on airway cells further support lung system relevance.

• beta and delta tocopherolsScientific

  Mixed tocopherol preparations containing delta-tocopherol have been tested in human clinical trials for lung inflammation in asthma and following airway pollutant exposure. A gamma-tocopherol-enriched supplement (also containing 167 mg delta-tocopherol per softgel) reduced sputum eosinophilia in asthma patients in an RCT. Dietary intake of all four tocopherol forms including delta has been investigated for lung cancer risk reduction.

• beta-caroteneScientific

  The relationship between beta-carotene and the lungs is defined by landmark RCT evidence: high-dose supplementation (20–30 mg/day) significantly increased lung cancer incidence in smokers and asbestos-exposed individuals in the ATBC and CARET trials, with 18–28% excess lung cancer incidence. Dietary beta-carotene levels in non-smokers are inversely associated with lung cancer risk in observational studies.

• black cuminScientific

  Clinical trials in asthma patients confirm N. sativa (1–2 g/day seeds or 1 g/day oil for 3–12 weeks) improves pulmonary function tests and reduces asthma symptoms. Experimental studies show TQ reduces eosinophilic and lymphocytic lung inflammation and prevents mustard-induced lung damage.

• blackboard treeScientific

  A. scholaris is specifically noted as a traditional treatment for lung diseases, with preclinical evidence for antitussive, antiasthmatic, expectorant, and pulmonary anti-inflammatory effects from indole alkaloids. Animal models demonstrate reduction in airway inflammation and bronchoconstriction.

• borageScientific

  Borage-derived GLA has scientific evidence for lung benefit in two clinical contexts: bronchial asthma (Phase 2 RCT showing significant symptom improvement) and ARDS (multicenter RCT showing reduced pulmonary neutrophil recruitment, improved oxygenation, and fewer ventilator days with EPA+GLA enteral nutrition). Traditional use also covers general lung conditions including bronchitis and pleurisy.

• boswelliaScientific

  Boswellia (Boswellia serrata, Indian frankincense) has a long history in Ayurvedic medicine for asthma, cough, and chronic lung inflammation. Boswellic acids are specific inhibitors of 5-lipoxygenase (5-LOX), blocking leukotriene biosynthesis implicated in bronchoconstriction and airway inflammation. A double-blind placebo-controlled clinical study (Eur J Med Res, 1998) demonstrated significant improvement in bronchial asthma patients taking Boswellia extract over 6 weeks.

• boswellic acidScientific

  Boswellic acids are the active constituents of Boswellia serrata resin, functioning as specific inhibitors of 5-lipoxygenase (5-LOX) and human leukocyte elastase—both central to airway inflammation and lung tissue destruction. A 1998 double-blind, placebo-controlled 6-week RCT demonstrated significant improvement in bronchial asthma patients. AKBA is considered the most potent component for respiratory anti-inflammatory activity.

• broccoliScientific

  Sulforaphane from broccoli induces phase II enzymes in lung tissue and has been investigated in clinical trials for lung cancer chemoprevention in former smokers. The large China RCT documented enhanced detoxification of airborne carcinogens including those relevant to lung cancer. Results for airway inflammation are mixed.

• bromelainScientific

  Bromelain, a proteolytic enzyme from pineapple, has documented anti-inflammatory activity relevant to the respiratory tract, including reduction of nasal and sinus inflammation. Preclinical studies demonstrate bronchodilator and anti-asthmatic activity. Clinical evidence supports efficacy for acute nasal and sinus inflammation as adjunct to standard care. Nasal administration in animal models showed enhanced localization to lung tissue and anti-asthmatic activity.

• butterburScientific

  Butterbur's antispasmodic and anti-leukotriene mechanisms act directly on airway smooth muscle, with clinical studies demonstrating improved FEV1 and reduced bronchial reactivity in asthma and chronic obstructive bronchitis patients. MSKCC and StatPearls/NIH confirm human study evidence for pulmonary effects.

• catalaseScientific

  Catalase activity in bronchoalveolar lavage fluid is reduced in asthma patients due to oxidative inactivation, contributing to airway oxidative stress and inflammation. Catalase is part of the pulmonary antioxidant defense system against both endogenous ROS and inhaled environmental oxidants. Lung hypoxia/reoxygenation injury is associated with specific changes in endogenous lung catalase activity.

• chaff flowerScientific

  A. aspera shows pharmacological bronchodilator activity in preclinical models (PubMed-indexed study) and is traditionally used for pneumonia. Its expectorant saponins and anti-inflammatory properties support lung health.

• chlorellaScientific

  A clinical RCT in 97 COPD and asthma patients demonstrated chlorella extract significantly improved pulmonary antioxidant enzyme levels (SOD, CAT, GPx, glutathione) as adjunctive therapy. Spirometric outcomes did not significantly improve, and a murine COPD model showed anti-inflammatory and structural lung benefits.

• cloveScientific

  Eugenol has demonstrated anti-inflammatory effects in LPS-induced lung injury animal models, reducing lung inflammation and preserving lung function. Antimicrobial activity against respiratory pathogens and traditional expectorant use add further relevance.

• coleus forskohliiScientific

  Coleus forskohlii and its active compound forskolin are clinically studied bronchodilators for asthma. Multiple small human trials demonstrate reduced asthma attack frequency, improved FEV1, and anti-inflammatory effects in airway tissue. Inhaled, oral, and IV administration routes have been tested.

• cordycepsScientific

  Cordyceps sinensis has been used in TCM for centuries to 'soothe the lung' for respiratory diseases. A 2019 systematic review and meta-analysis of 15 RCTs (1,238 participants) published in Evidence-Based Complementary and Alternative Medicine found Cordyceps supplementation showed potential benefits in lung function, exercise endurance, and quality of life in stable COPD patients. Animal studies confirm it reduces airway remodeling, airway wall thickening, and lung fibrosis.

• cryptoxanthinScientific

  BCX intake is inversely associated with lung cancer risk in large prospective human studies (15–40% risk reduction). It prevents cigarette smoke-induced lung inflammation, oxidative damage, and squamous metaplasia in animal models. BCX suppresses NF-κB and AP-1 in lung tissue and inhibits human bronchial cancer cell growth in vitro.

• curcuminScientific

  Curcumin, the principal bioactive polyphenol of turmeric, has extensive preclinical and emerging clinical evidence for lung conditions including asthma, COPD, pulmonary fibrosis, and acute lung injury. It acts as an antioxidant and anti-inflammatory by inhibiting NF-κB and reducing IL-4, IL-5, IL-13, and TNF-α. PMC review (PMC12046236) confirms curcumin's antioxidant and anti-inflammatory role in respiratory disease.

• delta-tocopherolScientific

  Delta-tocopherol is more active than α- or γ-tocopherol in inhibiting lung tumor growth in xenograft animal models. Epidemiological data link dietary tocopherol intake (including delta form) inversely to lung cancer risk. Tocopherols suppress LPS-induced oxidative stress and inflammatory cytokine release in lung cell models. The anti-inflammatory and antioxidant activity of δ-tocopherol is directly relevant to the oxidative environment of the lung.

• DHA (docosahexaenoic acid)Scientific

  DHA specifically — more than EPA or other omega-3s — is associated with preserved lung function (FEV1 and FVC), attenuated lung function decline, and lower odds of developing airway obstruction in large population studies. DHA-derived resolvins also appear active in resolving lung inflammation in COPD and acute respiratory conditions.

• docosahexaenoic acidScientific

  DHA and EPA modulate pulmonary inflammation via eicosanoid and cytokine pathways relevant to asthma and airway inflammatory conditions. DHA-derived resolvins and protectins promote resolution of eosinophilic airway inflammation. Maternal DHA supplementation may reduce offspring asthma and allergy risk. DHA is relevant to bronchopulmonary dysplasia risk in preterm infants.

• echinaceaScientific

  Echinacea (E. purpurea, E. angustifolia) is among the most clinically studied herbs for respiratory tract infections. A 2015 PubMed meta-analysis of RCTs found it significantly lowers the risk of recurrent respiratory infections and complications via immunomodulatory, antiviral, and anti-inflammatory mechanisms. A 2023 systematic review (PMC10537612) confirmed mechanistic evidence for URTI treatment through mucosal immunostimulation.

• echinacea purpureaScientific

  E. purpurea has directly relevant clinical and mechanistic evidence for the lungs via its antiviral, anti-inflammatory, and immunomodulatory actions on respiratory viral pathogens. Multiple RCTs have measured pulmonary outcomes including viral loads in the respiratory tract, symptom severity, and infection incidence.

• EGCG (epigallocatechin gallate)Scientific

  EGCG protects lung tissue from cigarette smoke-induced damage, LPS-induced acute lung injury, bleomycin-induced fibrosis, and PM2.5-triggered oxidative inflammation through antioxidant and anti-inflammatory mechanisms. It reduces airway mucus production, neutrophil recruitment, and collagen deposition in multiple preclinical models.

• elderScientific

  Elder (Sambucus nigra) encompasses both the berry and flower (elderflower), both historically used for respiratory conditions. Elderflower is Commission E-approved as a diaphoretic for colds and fever, with anti-catarrhal and expectorant properties. Elderberries have RCT evidence reducing influenza duration by 4 days. Active flavonoids and anthocyanins provide antiviral and immunostimulatory mechanisms.

• elderberryScientific

  Elderberry (Sambucus nigra) has well-documented clinical evidence for reducing duration and severity of upper respiratory tract infections (influenza, colds). A 2016 randomized, double-blind study found elderberry supplementation significantly reduced cold duration and severity in air travelers. Active anthocyanins and flavonoids exert antiviral, immunostimulatory, and anti-inflammatory effects on respiratory mucosa.

• eucalyptusScientific

  Eucalyptus oil and 1,8-cineole exert multiple documented pharmacological effects on lung tissue including bronchodilation, mucociliary clearance enhancement, anti-inflammatory activity, and antimicrobial action against respiratory pathogens. Multiple human RCTs in asthma and COPD confirm clinically significant pulmonary benefits. These are among the most robustly evidenced therapeutic applications of eucalyptus.

• forskohlii rootScientific

  Forskolin bronchodilates airways via cAMP-mediated smooth muscle relaxation and suppresses allergic mediator release in lung tissue. Human trials with oral and inhaled/IV forskolin demonstrate bronchodilation and reduction in asthma attacks.

• forsythiaScientific

  Forsythia suspensa is classified in TCM as acting on the lung meridian and has extensive preclinical evidence for protecting lung tissue against acute injury, viral pneumonia, pulmonary fibrosis, and respiratory syncytial virus infection. It is a key ingredient in combination formulas used clinically in China for lung infections. Preclinical evidence is strong; standalone human clinical trial evidence is absent.

• fritillaryScientific

  The lung is the primary target organ of fritillary. Preclinical evidence covers acute lung injury attenuation, pulmonary anti-fibrotic effects, protection of bronchial epithelial cells from oxidative damage, and structural/functional preservation in COPD models. The Chinese Pharmacopoeia assigns lung-moistening as its primary action.

• ganodermaScientific

  Ganoderma lucidum (Reishi, Lingzhi) is a medicinal mushroom with TCM documentation for lung conditions dating back to the Shennong Bencao Jing. It regulates Th1/Th2 cytokine balance, inhibits histamine release from mast cells, and has anti-inflammatory and immunomodulatory effects relevant to asthma and COPD. Scientific literature documents its use alongside Cordyceps as one of the primary medicinal mushrooms for lung conditions.

• garlicScientific

  Garlic's allicin and sulfur compounds demonstrate anti-inflammatory and antioxidant effects in respiratory tissue, and a large cohort study associated regular raw garlic consumption with significantly lower lung cancer risk. Preclinical evidence shows garlic oil blocks NF-κB/NLRP3 signaling in acute lung injury. Traditional use for respiratory ailments spans multiple ancient cultures.

• geraniumScientific

  Pelargonium (primarily P. sidoides) has robust clinical evidence for pulmonary conditions including acute bronchitis, with EMA approval and Cochrane review support. P. graveolens EO inhalation has respiratory anti-inflammatory and antimicrobial effects relevant to lung health.

• gingerScientific

  Ginger (Zingiber officinale) has traditional use across Ayurvedic, TCM, and Western herbal systems for respiratory conditions including cough, bronchitis, and asthma. Scientific evidence demonstrates it acts as a natural bronchodilator by relaxing airway muscles, reduces airway inflammation, and may improve lung capacity. Active constituents gingerols and shogaols inhibit pro-inflammatory cytokines and arachidonic acid metabolism relevant to airway disease.

• ginkgo bilobaScientific

  Ginkgo biloba has been investigated for pulmonary applications due to its potent PAF antagonism and anti-inflammatory properties relevant to airway inflammation. A clinical trial registered with ClinicalTrials.gov assessed its efficacy in mild-to-moderate asthma. The respiratory evidence base is limited but mechanistically grounded.

• ginsengScientific

  Ginseng (Panax ginseng, P. quinquefolius) has been used in TCM for thousands of years to benefit the lungs and treat respiratory symptoms. Clinical trials show ginseng reduces recurrence of colds and flu, and several controlled trials in COPD patients showed promising improvement in lung function and exercise capacity. A 2021 PMC review confirmed ginseng's pharmacological efficacy against respiratory tract infections via immunomodulatory, antiviral, and antibacterial mechanisms.

• glehnia littoralisScientific

  G. littoralis is one of the most important TCM herbs for lung conditions and is listed in the Chinese Pharmacopoeia for clearing lung heat and moistening lung dryness. Antitussive and lung-protective pharmacological effects are documented in the 2023 systematic review. Preclinical anti-inflammatory data support airway applications.

• green chirettaScientific

  Green chiretta's best-documented clinical effects directly involve the lungs, via its activity in acute lower and upper respiratory tract infections, cough, and bronchial inflammation. Over 33 RCTs and a major meta-analysis confirm clinically meaningful pulmonary symptom reduction.

• hedychium spicatumScientific

  Lung health is a primary locus of H. spicatum pharmacological activity, with preclinical bronchodilator, antihistaminic, and anti-asthmatic effects demonstrated in guinea pig and rat respiratory models. The essential oil component 1,8-cineole and β-sitosterol are documented lung-active compounds. Ayurvedic tradition places the plant among primary pulmonary herbs.

• hesperidinScientific

  Hesperidin protects lung tissue from inflammatory injury in asthma, COPD, pulmonary fibrosis, ARDS, and COVID-19-related pneumonia models. It inhibits NF-κB, iNOS, and COX-2 in lung tissue; reduces inflammatory cell infiltration; activates the ERK/Nrf2 antioxidant pathway in the lungs; and has anti-fibrotic effects relevant to pulmonary fibrosis.

• honeyScientific

  Honey reduces cough frequency, severity, and duration in respiratory infections, and has demonstrated antiviral activity against influenza and varicella-zoster viruses. Cochrane (2018, 6 RCTs, 899 children) and a 2021 BMJ Evidence-Based Medicine meta-analysis confirm honey's pulmonary symptom benefits. A Phase III RCT in 269 TB patients found honey significantly improved sputum clearance.

• honeysuckleScientific

  L. japonica is assigned to the Lung meridian in TCM and is extensively used for lung infections. Preclinical studies show protective effects against PM2.5-induced pulmonary damage via TGF-β and NF-κB pathways, and against LPS/ovalbumin-induced pulmonary cytotoxicity. Antiviral activity against influenza and RSV is documented.

• horseradishScientific

  Horseradish has the strongest clinical evidence for its effects on pulmonary conditions. Multiple studies of Angocin Anti-Infekt N demonstrate efficacy for acute bronchitis comparable to antibiotics. ITCs are excreted via the lungs, providing direct antimicrobial and anti-inflammatory activity at pulmonary epithelium. German Commission E endorses use for respiratory infections.

• houttuyniaScientific

  Houttuynia cordata (Yu Xing Cao, fish-mint) is a primary TCM herb for lung heat, used for pulmonary abscess, cough with purulent sputum, and respiratory infections. Scientific studies confirm it significantly inhibits a variety of pathogenic microorganisms, strengthens immune function, relaxes bronchial smooth muscle, and produces antitussive and antiasthmatic effects. It is used in clinical COPD protocols in China.

• hyssopScientific

  Hyssop has a strong traditional and growing scientific basis for lung-specific effects. A clinical RCT demonstrated improvements in pulmonary function tests in asthmatic patients. Animal studies confirm reduction of airway inflammation. Traditional use for bronchitis, asthma, and lung congestion spans Persian, Uyghur, and European medicine.

• indian frankincenseScientific

  The lungs are a directly studied organ for Boswellia. The 1998 asthma RCT (PubMed PMID 9810030) measured and improved FEV1, FVC, and PEFR — objective pulmonary function tests — in 70% of treated patients vs. 27% placebo. Traditional Ayurvedic texts document Boswellia for chronic lung disease.

• indole-3-carbinolScientific

  I3C has direct human clinical evidence for activity against HPV-driven respiratory papillomatosis affecting the larynx and airways. Prospective clinical trials in both adults and children show ~33% remission rates. Preclinical models demonstrate I3C inhibits tobacco smoke carcinogen-induced lung adenocarcinoma. The clinical evidence is limited to uncontrolled or phase I designs; no placebo-controlled RCT has been published for respiratory disease.

• L-citrullineScientific

  The L-citrulline–L-arginine–NO axis is critically important in pulmonary vascular tone regulation, and its impairment underlies pulmonary hypertension, bronchopulmonary dysplasia, asthma, and COPD. A human clinical trial in 25 patients with idiopathic PAH or Eisenmenger Syndrome showed L-citrulline malate reduced mean pulmonary artery pressure and improved 6-minute walk distance. Neonatal lung research has established citrulline supplementation as a strategy for PH associated with BPD.

• L-cysteineScientific

  L-cysteine/NAC is among the most evidence-supported supplements for lung tissue health, maintaining pulmonary glutathione concentrations that protect against oxidative damage, reducing mucus viscosity, limiting inflammatory cytokine production in bronchial epithelium, and slowing disease progression in chronic obstructive and fibrotic lung diseases.

• lactobacillus rhamnosusScientific

  L. rhamnosus GR-1 prevented allergic asthma-related airway function deterioration and promoted gut microbiome resilience in murine models. L. rhamnosus D3189 reduced RSV shedding and viral replication in primary nasal (and upper airway-connected) epithelial cells. The gut-lung axis is the primary mechanism by which oral L. rhamnosus exerts pulmonary effects.

• licorice rootScientific

  Licorice root (Glycyrrhiza glabra, G. uralensis) is a central herb in TCM, Ayurveda, and Western herbal traditions for respiratory conditions. Its primary active compounds—glycyrrhizin and glycyrrhizinic acid—exert expectorant, anti-inflammatory, antiviral, and demulcent effects on the respiratory mucosa. Traditional Chinese medicine pharmacopeia documents its use for moistening the lung and relieving cough. Modern evidence confirms anti-asthmatic, anti-inflammatory, and antiviral properties.

• limoneneScientific

  Limonene has documented protective effects against lung injury and allergic pulmonary inflammation in preclinical models. It reduces BALF eosinophils, macrophages, and Th2 cytokines in asthma models and attenuates acute lung injury through cytokine suppression. These effects are mechanistically coherent and replicated across independent studies.

• lobeliaScientific

  Alpha-lobeline is a well-characterized respiratory stimulant that activates carotid and aortic chemoreceptors, dilates bronchioles, and promotes expectoration. Animal studies confirm transitory hyperpnea and increased expiratory airflow. These pulmonary effects have pharmacological grounding though human clinical trials for lung conditions have not demonstrated efficacy.

• luteolinScientific

  Luteolin's pulmonary effects are among the most systematically reviewed of any organ system, with evidence across ALI, COPD, asthma, pulmonary fibrosis, and pneumonia models, all mediated through convergent anti-inflammatory and antioxidant signaling mechanisms.

• lycopeneScientific

  Lycopene is present in lung epithelial lining fluid and macrophages, where it protects against oxidative damage from ozone, smoke, and environmental toxins. A small RCT showed lycopene supplementation increased lung macrophage lycopene by 12% and reduced ozone-induced lung epithelial DNA damage by 20%. A COPD pilot RCT (20 mg/day, 4 months) found improvements in oxidative stress and inflammatory markers.

• malabar nutScientific

  Adhatoda vasica has the most extensive pharmacological evidence for the lungs among all body systems, with bronchodilatory, mucolytic, expectorant, anti-inflammatory, and mucoprotective effects confirmed across multiple study designs including human RCTs.

• mucinScientific

  Airway mucins (primarily MUC5AC and MUC5B) are the major structural components of lung mucus, and their dysregulation is a defining pathological feature of COPD, cystic fibrosis, and asthma documented in clinical studies. Mucin overproduction in the airway lumen obstructs airflow, impairs mucociliary clearance, and promotes bacterial colonization. Lung-specific mucin expression is measurable in bronchoalveolar lavage fluid and bronchial biopsies from patients.

• mugwortScientific

  A. vulgaris demonstrates pharmacologically confirmed broncholytic and antispasmodic activity on pulmonary smooth muscle via dual muscarinic and calcium channel blockade. The essential oil's dominant constituent 1,8-cineole provides mucolytic activity. Traditional use as an expectorant for bronchitis is well documented. No human pulmonary RCTs exist.

• mulleinScientific

  Mullein (Verbascum thapsus) has extensive traditional use across Native American, Eclectic, and European herbal medicine systems for respiratory conditions including bronchitis, cough, asthma, and tuberculosis. Its saponins act as natural expectorants, flavonoids (verbascoside) provide anti-inflammatory activity in bronchial passages, and mucilage soothes irritated mucous membranes. Antimicrobial activity against Streptococcus pneumoniae, including drug-resistant strains, has been demonstrated.

• NAC (N-acetyl cysteine)Scientific

  NAC is one of the most extensively researched respiratory supplements in clinical medicine. It acts as a mucolytic by breaking disulfide bonds in mucus, a glutathione precursor replenishing airway antioxidant defenses, and an anti-inflammatory agent inhibiting NF-κB and IL-6. Multiple RCTs and meta-analyses support its use in COPD, chronic bronchitis, cystic fibrosis, and bronchiectasis, with high-dose NAC (≥1200 mg/day) showing reduction in exacerbation risk.

• naringinScientific

  Naringin suppresses airway inflammation and ameliorates pulmonary endothelial hyperpermeability in LPS/cigarette smoke-exposed mice by upregulating Aquaporin-1. It also exerts anti-inflammatory effects relevant to asthma and lung injury models. Evidence is entirely preclinical.

• nigella seedScientific

  Nigella sativa (black seed, black cumin) has well-documented anti-inflammatory and bronchodilatory effects validated in multiple clinical trials for asthma and allergic rhinitis. Its active constituent thymoquinone inhibits 5-LOX, COX, and reduces mast cell histamine release. Multiple small RCTs and a growing clinical literature confirm significant improvement in asthma symptoms, FEV1, and peak expiratory flow rate.

• omega-3 fatty acidsScientific

  Omega-3 fatty acids have anti-inflammatory effects on lung tissue, with clinical evidence in cystic fibrosis (improved lung function) and epidemiological associations with lower asthma risk. Anti-inflammatory prostaglandin and leukotriene modulation provides a mechanistic basis for bronchodilatory and cytoprotective effects in the airways.

• onionScientific

  Onion constituents produce direct bronchodilatory, anti-inflammatory, and antihistaminic effects on lung tissue. Quercetin and isoquercitrin reduce inflammatory cell infiltration in bronchoalveolar lavage fluid, inhibit PAF-induced bronchial obstruction, and suppress Th2 cytokines driving eosinophilic airway inflammation.

• palmitic acidScientific

  Palmitic acid is the structural backbone of dipalmitoylphosphatidylcholine (DPPC), the principal component of pulmonary surfactant. DPPC's fully saturated palmitic acid chains enable tight molecular packing that is essential for reducing alveolar surface tension and preventing lung collapse on exhalation. Free palmitic acid also enhances surfactant surface activity and confers resistance to inhibition by blood proteins in surfactant preparations.

• peppermintScientific

  Peppermint (Mentha x piperita) contains menthol, which acts as a decongestant and antispasmodic on respiratory passages. Traditional use across European, Ayurvedic, and Chinese medicine systems includes cough, colds, and bronchitis. Menthol activates TRPM8 cold receptors in airways, creating a sensation of improved airflow and soothing bronchial spasms. Commission E approves peppermint oil for internal use for conditions of the respiratory tract.

• perillaScientific

  Perilla fruit water extract reduces LPS-induced lung inflammation and neutrophil infiltration in animal ARDS models via MAPK/JNK-AP-1/c-Fos signaling. Perilla leaf extract suppresses pro-allergic and pro-inflammatory cytokines in human bronchial epithelial cells. Perilla seed extracts reduce MUC5AC mucin production in PM2.5-exposed human nasal cells.

• picrorhiza kurroaScientific

  P. kurroa extracts and the compound androsin have mechanistically documented anti-PAF and anti-inflammatory activity in the lungs, demonstrated in preclinical models. Multiple Indian clinical trials and a systematic review address P. kurroa specifically for bronchial/lung disease.

• pineappleScientific

  Animal studies show bromelain reduces lung inflammation, eosinophil infiltration, and airway hyperreactivity in asthma models. Clinical data from sinusitis trials and recovery from respiratory infections suggest systemic respiratory anti-inflammatory activity. Bromelain is included in traditional preparations for lung congestion.

• pistacia integerrima gallScientific

  P. integerrima galls directly target lung tissue through bronchodilatory, anti-inflammatory, and mast-cell stabilizing effects validated in animal models. An ovalbumin-induced allergic asthma mouse study showed reduced pulmonary edema (via AQP1/AQP5 elevation) and attenuated airway cytokine expression at 200 mg/kg. The 2014 PubMed spirometry study in rats provides direct lung function evidence.

• plantagoScientific

  Clinical studies demonstrate Plantago major improves FEV1 and FVC in asthmatic patients and reduces lung inflammation in experimental COPD and asthma models. Commission E and ESCOP endorse P. lanceolata for airway catarrh. A double-blind RCT confirmed P. major syrup reduced bronchitis severity.

• platycodonScientific

  Platycodon grandiflorum (balloon flower, jie geng) is a foundational TCM herb specifically assigned to the lung meridian, used for thousands of years for cough, phlegm, sore throat, and pulmonary abscess. Its active saponins (platycodins) relax bronchial smooth muscle and modulate respiratory tract mucosal immunity. A PMC study documented Platycodon's effectiveness in chronic bronchitis via polysaccharide-mediated reduction of mucus secretion, cough, and gasp.

• platycodon rootScientific

  Platycodon root (Platycodon grandiflorum, jie geng) is a canonical TCM herb for the lung meridian. Its saponins relax bronchial smooth muscle, modulate respiratory mucosal immunity, and exert expectorant and anti-inflammatory effects. Used for cough, phlegm, pulmonary abscess, and hoarseness for thousands of years in Chinese, Korean, and Japanese medicine. PMC research confirms anti-chronic bronchitis effects via polysaccharide mechanisms.

• purslaneScientific

  A small clinical trial in asthma patients demonstrated purslane extract produced pulmonary function improvements comparable to theophylline. Reviews confirm bronchodilatory and antiasthmatic properties. Traditional use for lung-related conditions (asthma, cough, shortness of breath) is documented widely across ethnobotanical traditions.

• quercetinScientific

  Quercetin is a flavonoid with well-documented anti-inflammatory activity relevant to the lungs, including inhibition of 5-lipoxygenase and COX enzymes, mast cell stabilization blocking histamine and leukotriene release, and antiviral activity against respiratory viruses. Multiple preclinical studies demonstrate benefit in fibrotic lung models, acute lung injury, and asthma models. Clinical trials in COPD have been registered (NCT01708278), and quercetin showed promising respiratory symptom improvement in COVID-19 trials.

• reishi mushroomScientific

  Reishi (Ganoderma lucidum) has extensive use in TCM for lung conditions and is described as having the most wide-ranging indications for lung and liver support among medicinal mushrooms. Scientific studies document immunomodulatory, anti-inflammatory, and antihistamine-like properties relevant to respiratory disease. Research shows benefit in asthma and chronic respiratory conditions through regulation of Th1/Th2 balance and inhibition of histamine release from mast cells.

• rosmarinic acidScientific

  Rosmarinic acid demonstrates lung-protective properties in systemic injury models and preclinical asthma/allergic models, reducing pulmonary inflammatory cell infiltration, NF-κB-driven cytokine production, and oxidative lung injury markers. Human evidence via the allergic rhinoconjunctivitis clinical trial is mechanistically relevant to upper airway/lung inflammatory disease.

• safflowerScientific

  HSYA (hydroxysafflor yellow A) has demonstrated preventive and therapeutic effects on multiple respiratory conditions in preclinical models, including acute lung injury, pulmonary fibrosis (bleomycin model), and asthma. Safflower compounds isolated from flowers show protective effects against LPS-induced BEAS-2B lung cell injury. SY distributes to lung tissue at relatively high concentrations after oral administration. Traditional Persian medicine used safflower to treat respiratory ailments and chronic bronchitis.

• schizonepetaScientific

  Schizonepeta's volatile oil demonstrated anti-inflammatory effects in a rat carrageenan-induced pleurisy (pleural/lung inflammation) model (Shan et al., J Ethnopharmacol 2016). Antiviral effects against respiratory viruses are also preclinically documented. Traditional use for pulmonary conditions is well-established.

• secoisolariciresinol diglucosideScientific

  SDG protects non-malignant lung cells from radiation-induced DNA damage, reduces pulmonary oxidative stress and inflammation, prevents radiation-induced pulmonary fibrosis, and upregulates cytoprotective antioxidant enzymes (HO-1, GSTM1, NQO1) in lung tissue. An ex vivo human lung slice model confirmed SDG analog LGM2605 protected against proton radiation injury. Dietary flaxseed (SDG source) also reduced oxidative lung injury in hyperoxia and ischemia/reperfusion models.

• serratiopeptidaseScientific

  Serratiopeptidase has clinical trial evidence for benefiting lung health through reduction of sputum viscosity, elasticity, and neutrophil burden in chronic airway disease. A 2003 RCT (Nakamura et al., Respirology) and a 1983 Japanese RCT both demonstrated significant mucolytic and anti-inflammatory effects in chronic pulmonary disease. Its elastase inhibition also reduces bronchial injury and improves mucociliary clearance.

• sophoraScientific

  S. flavescens flavonoids significantly suppress pro-inflammatory mediators in lung alveolar macrophages and reduce macrophage infiltration in granulomatous lung inflammation. Oxymatrine has anti-inflammatory and immunomodulatory effects relevant to pulmonary conditions. These findings are documented in peer-reviewed studies.

• SPMs (specialized pro-resolving mediators)Scientific

  The lungs are a primary site of SPM biosynthesis and action, with SPMs constitutively produced in alveolar macrophages and bronchial epithelial cells. Reduced SPM levels have been measured in human BAL fluid in ARDS, COPD, and asthma. Omega-3 supplementation increases lung SPM levels measurable in human BAL.

• stigmasterolScientific

  Stigmasterol reduces airway inflammation, mucus hypersecretion, and bronchoconstriction in OVA-asthmatic mouse models by targeting Th17 cytokines, TGF-β1/Smad2 signaling, and the substance-P/NK1-R neurogenic inflammation axis.

• tartarian asterScientific

  Aster tataricus has multiple documented preclinical mechanisms in the lungs, including protection against acute lung injury, anti-pulmonary fibrosis activity, antiviral effects reducing lung pathology in influenza models, and classic expectorant/antitussive properties. Traditional use as the central lung herb in TCM spans over 2,000 years.

• thymeScientific

  Thyme (Thymus vulgaris) has a well-established role in European herbal tradition and modern phytotherapy for respiratory conditions. Commission E and ESCOP approve Thyme herb for symptoms of bronchitis and upper respiratory catarrh. Thymol and carvacrol act as expectorants, bronchospasmolytic agents, and antimicrobials. A registered clinical trial (NCT02981147) evaluated thyme+ivy extract for acute cough, and laboratory research confirms antispasmodic and ciliary clearance effects.

• thymoquinoneScientific

  Thymoquinone is the primary bioactive constituent of Nigella sativa (black seed), with well-documented anti-inflammatory and bronchodilatory activity relevant to asthma and COPD. It inhibits 5-lipoxygenase, COX-2, and NF-κB while stabilizing mast cells. Multiple in vitro, animal, and some clinical studies specifically document its lung-protective and antiasthmatic effects.

• thymusScientific

  See Lung Health condition entry. Thyme's actions on the lungs—secretolysis, bronchospasmolysis, antimicrobial activity against pulmonary pathogens, and anti-inflammatory cytokine modulation—are documented by multiple clinical RCTs and are formally recognised by German Commission E, ESCOP, and EMA HMPC.

• tomatoScientific

  A randomized crossover clinical trial found tomato extract and tomato juice (45 mg lycopene/day, 7 days) significantly reduced airway neutrophil influx and sputum neutrophil elastase in asthmatic adults, indicating a protective effect on pulmonary inflammatory processes. Lycopene has also been associated with reduced respiratory disease risk in epidemiological studies.

• turmericScientific

  Turmeric (Curcuma longa) contains curcuminoids with extensive documented anti-inflammatory and antioxidant properties relevant to lung conditions. Used in Ayurveda and TCM for respiratory conditions including cough and asthma. Anti-inflammatory properties listed in an IntechOpen (2024) systematic review for respiratory disease management. Active curcumin inhibits NF-κB and reduces airway inflammatory mediators.

• tylophoraScientific

  Multiple controlled clinical trials in bronchial asthma patients have documented objective improvements in lung function parameters — FEV1, vital capacity, peak expiratory flow rate — following Tylophora treatment. Reductions in eosinophilic airway inflammation and suppression of bronchospasm are also documented. These findings constitute direct scientific evidence for a Tylophora–lung relationship.

• vitamin AScientific

  Vitamin A is required for lung alveolar development and maintenance. Deficiency impairs alveologenesis and causes structural lung changes; retinoic acid signaling governs alveolar septation. A causal beneficial effect of vitamin A (carotene) on adult lung function (FVC) was demonstrated using Mendelian randomization in 150,000 UK Biobank participants.

• vitamin CScientific

  Vitamin C protects lung tissue from oxidative damage and is depleted in chronic lung diseases. Supplementation ≥400 mg/day significantly improves FEV1% in COPD patients in meta-analyses of RCTs, and dietary vitamin C intake correlates positively with FEV1 and FVC in population studies.

• watercressScientific

  Human data demonstrate PEITC from watercress inhibits lung carcinogen NNK activation in smokers, providing direct mechanistic chemoprevention evidence. Cell studies confirm PEITC suppresses non-small cell lung cancer cell invasion and migration. Traditional expectorant use for lung conditions is additionally documented across multiple cultures.

• yarrowScientific

  Animal studies demonstrate bronchodilatory activity of A. millefolium via calcium channel-dependent relaxation of airway smooth muscle. The essential oil contains 1,8-cineole with documented mucolytic/expectorant properties. Traditional use for respiratory illness, approved by Commission E for fever and cold, encompasses lung function.

• abies spectabilisTraditional

  Pulmonary diseases including asthma, bronchitis, and cough are primary traditional indications for A. spectabilis. Preclinically confirmed antitussive and bronchodilatory activities support lung-relevant pharmacological potential.

• agrimonyTraditional

  Agrimony is used in Bulgarian and Central European folk medicine for inflammatory diseases of the lungs. Traditional preparations include infusions and decoctions for pulmonary complaints. The herb's expectorant and antimicrobial properties provide mechanistic plausibility. No clinical trial data exist.

• apricotTraditional

  Bitter apricot kernel (xing ren) is one of the most important TCM herbs for the Lung organ system, used to moisten the lungs, stop coughing, and calm wheezing. Its documentation spans from the earliest Chinese herbal classics to contemporary TCM practice. It is a core ingredient in widely-used respiratory formulas. The TCM 'Lung' system encompasses both respiratory and immune functions.

• asparagusTraditional

  Multiple traditional systems document asparagus for lung and bronchial conditions including asthma, cough, and coughing with blood. A. cochinchinensis is listed in the Chinese Pharmacopoeia for asthma and cough. A. racemosus extracts show antitussive effects. No human clinical trial evidence exists for lung-specific outcomes.

• assam indigoTraditional

  In TCM, Indigo Naturalis (S. cusia) is described as acting on the lung meridian and is traditionally used for hemoptysis (coughing blood) and respiratory viral infections. The classical materia medica texts spanning Tang through Qing dynasties document pulmonary indications.

• bambooTraditional

  Bamboo preparations have been used for over 2,500 years in TCM and across Ayurvedic, Siddha, and Unani systems specifically targeting the lungs. Multiple bamboo preparations enter the lung meridian in TCM and are used for lung-heat disorders, phlegm in the lungs, bronchitis, and pneumonia. These represent some of the most consistently documented applications of bamboo across Asian medical traditions.

• bayberryTraditional

  Bayberry has traditional use for pulmonary conditions including bronchitis, asthma, coughs, and excess phlegm. It was used in composition powder for chest complaints. Jethro Kloss's herbal text references bayberry for pulmonary hemorrhage. The herb is classified as an expectorant in traditional medicine.

• black pepperTraditional

  Black pepper is used in classical Ayurvedic medicine specifically for lung problems with sticky mucus, including as part of the Trikatu formula. Its anti-inflammatory, expectorant, and antimicrobial properties are relevant to lung health. Piperine has been included in COPD-related quality of life studies.

• black spruceTraditional

  The lungs are a primary traditional target of black spruce therapy, reflected in Indigenous chest salve use, the British Herbal Pharmacopoeia, and aromatherapy references for asthma, bronchitis, and cough. Bornyl acetate has preclinical evidence for anti-inflammatory activity in lung tissue.

• bonesetTraditional

  Boneset has a documented traditional role as a pulmonary remedy, used for bronchitis, pneumonia, and respiratory infections affecting the lungs. Its expectorant action to clear mucus and diaphoretic action to resolve fever were central to its use. Eclectic physicians employed it during the 1918 influenza pandemic partly to prevent pulmonary complications. No clinical lung-function studies exist.

• caesalpinia cristaTraditional

  C. crista is traditionally used in Ayurvedic and Unani medicine for respiratory disorders including asthma and cough. This use is documented across multiple independent ethnomedicinal traditions but lacks controlled preclinical or human respiratory studies.

• cajuputTraditional

  Cajuput oil has traditional use for lung-related conditions (coughs, bronchitis, asthma, pneumonia) throughout Southeast Asia and Australia, supported by its 1,8-cineole content acting as an expectorant and mucolytic. A 2026 animal study confirmed M. cajuputi extract modulates lung inflammatory cytokines (IL-6, IL-10) in a murine model. Direct lung clinical trials for cajuput are absent.

• camphor oilTraditional

  Camphor has traditional use for lung health including cough suppression, bronchitis, and clearing bronchial mucus via inhalation. Historical texts document its use in asthma and whooping cough. Clinical evidence for direct lung effects is limited; camphor's primary respiratory evidence relates to nasal/chest congestion rather than specific lung pathology.

• cardamomTraditional

  Cardamom is traditionally used to clear congestion from the lungs, ease cough, and support pulmonary function in Ayurvedic and South Asian medicine. The expectorant action is primarily attributed to 1,8-cineole. Antioxidant properties may protect lung tissue from oxidative damage. No human clinical trials specifically targeting lung function outcomes have been published for cardamom.

• chen piTraditional

  The Lungs are one of the three primary organ systems targeted by Chen Pi in TCM (alongside Spleen and Stomach). It is used to transform phlegm in the Lungs, reduce cough, and protect pulmonary tissue from inflammatory injury.

• chickweedTraditional

  Chickweed is traditionally used as a demulcent and expectorant herb with specific affinity for lung conditions including bronchitis, asthma, and dry coughs. Saponins loosen mucus secretions while mucilage soothes lung tissue. No clinical evidence is available.

• clerodendrum indicumTraditional

  C. indicum root is documented in multiple traditional systems as a lung medicine, being used for pulmonary complaints including asthma, bronchitis, cough, and scrofulous affections. The root is classified as expectorant and bronchodilatory in traditional systems, with a laboratory bronchodilatory compound having been identified.

• coixTraditional

  Coix seed enters the lung meridian in TCM and is used for lung carbuncle, pulmonary edema, wet pleurisy, and lobar pneumonia. Modern research shows cell-level anti-cancer activity in lung adenocarcinoma lines, but clinical respiratory endpoint trials are absent.

• coltsfootTraditional

  Coltsfoot is described in herbal traditions as 'nature's best herb for the lungs' and has been used for debilitated coughs, emphysema, silicosis, chronic bronchitis, and lung damage from smoking. TCM classifies it as entering the lung meridian. Traditional evidence is extensive; clinical trial evidence is absent.

• dioscoreaTraditional

  Dioscoreae Rhizoma is documented in the Chinese Pharmacopoeia and TCM texts as a herb that tonifies the lungs, used for cough and asthma. The antispasmodic properties are mechanistically relevant to bronchospasm. No clinical pulmonary evidence exists.

• dong quaiTraditional

  Classical TCM texts including Shennong's Classic of Materia Medica describe Dong Quai for 'cough, asthmatic attacks, and upward breathing.' Chinese herbalists have used the herb to strengthen lung meridians and it appears in traditional asthma and cough formulas. Ligustilide has demonstrated bronchial smooth muscle relaxation in isolated guinea-pig trachea. No human RCTs for respiratory conditions have been identified.

• elecampaneTraditional

  Elecampane (Inula helenium) root is a classic Western and Ayurvedic respiratory herb with centuries of documented use for chronic bronchitis, cough, asthma, bronchial catarrh, and tuberculosis-associated conditions. Its constituents inulin (mucilaginous, soothing and expectorant), alantolactone (volatile oil, anti-inflammatory, antimicrobial, expectorant), and sesquiterpene lactones provide its respiratory actions. It kills tuberculosis bacteria in vitro and is listed in historical pharmacopeias as a lung tonic.

• ferula assafoetidaTraditional

  Asafoetida's volatile oil is specifically eliminated through the lungs, making it uniquely active on pulmonary tissue. Traditional use for asthma, bronchitis, whooping cough, and mucus clearance is supported by tracheal smooth-muscle relaxation studies in animal models.

• fu lingTraditional

  In TCM, Fu Ling is classified as having an action on the Lung channel, resolving 'dampness and phlegm' affecting the Lungs and treating productive cough. The Chinese Pharmacopoeia includes phlegm as an indication. Animal research shows P. cocos extract modulates Th2 airway inflammation in an asthma model.

• glehnia rootTraditional

  The lungs are the primary organ target of glehnia root in TCM, where it is used to clear lung heat, moisten the lung, and treat lung yin deficiency. This is its most fundamental documented application across all traditional systems and pharmacopoeias.

• goji berryTraditional

  In TCM, goji berry is classified as entering the Lung channel, with documented traditional use for moistening dry lungs, easing dry cough, and treating consumptive cough from lung yin deficiency. The Compendium of Materia Medica specifically references lung health. Modern pharmacological evidence for direct pulmonary effects of goji is limited.

• goldenrodTraditional

  Goldenrod's traditional role as an anticatarrhal and diaphoretic herb extends to the lungs and bronchi, with traditional use for bronchitis and respiratory catarrh. Traditional materia medica lists it for emphysema and bronchitis. Anti-inflammatory and anticatarrhal actions of goldenrod constituents provide plausible mechanisms. No clinical pulmonary studies exist.

• gooseberryTraditional

  Traditional Ayurvedic and Unani medicine document amla as a pulmonary tonic. A clinical pilot study evaluated amla specifically for cardio-respiratory improvement in smokers with compromised lung function. Anti-inflammatory and antioxidant mechanisms support pulmonary protective effects.

• greek mountain teaTraditional

  GMT's traditional use for lung diseases—bronchitis, bronchial asthma, and lung emphysema—is consistently documented across Balkan ethnobotany and recognized in EU regulatory assessments. Multiple peer-reviewed reviews identify lung disease treatment as one of GMT's primary historical applications. No human pulmonary function clinical data have been published.

• guggulTraditional

  Guggul is used in Ayurveda for lung and bronchial conditions through its expectorant and anti-Kapha properties. Inhalation of guggul resin vapor is a traditional application for respiratory catarrh and bronchitis. No clinical evidence for lung-specific applications exists.

• horehoundTraditional

  The lungs are horehound's primary traditional target organ, with documented use for coughs, bronchitis, whooping cough, and asthma extending from ancient Egypt and Rome to present-day European regulatory approval. EMA HMPC and German Commission E recognise traditional use for cough. Marrubiin's stimulation of bronchial secretions provides mechanistic plausibility.

• immortelleTraditional

  H. italicum EO has traditional use for lung conditions including bronchitis, asthma, and cough. In vitro evidence confirms antibacterial and biofilm-inhibitory activity against lung-relevant pathogens (Streptococcus pneumoniae, Pseudomonas aeruginosa). No clinical evidence for lung-specific outcomes exists.

• indian gum arabic treeTraditional

  Acacia nilotica leaves are traditionally used to treat bronchitis, coughs, and chest pain. Anti-inflammatory and antispasmodic properties provide a pharmacological basis for pulmonary use. Traditional documentation of respiratory use is consistent across multiple cultures.

• indian sarsparillaTraditional

  Indian sarsaparilla is documented in traditional Indian medicine for bronchitis, cough, asthma, and respiratory complaints. Anti-asthmatic activity is noted in pharmacological reviews. The root's demulcent and membrane-repairing properties are specifically documented for lung complaints.

• inula racemosaTraditional

  I. racemosa is deeply embedded in Ayurvedic, Chinese, and Himalayan traditional medicine as a lung tonic, expectorant, and bronchodilator. It is indicated for pulmonary edema, lung congestion, emphysema, tuberculosis-related cough, and breathlessness in classical Ayurvedic texts and multiple ethnomedicinal traditions.

• knotweedTraditional

  In TCM, Hu Zhang is classified as entering the lung meridian and is used to resolve phlegm, ease cough, and treat bronchitis. Traditional Chinese prescriptions use knotweed for lung infections and cough. In vitro studies show PC constituents inhibit viral replication and airway smooth muscle proliferation. No human RCTs confirm pulmonary clinical efficacy.

• lilacTraditional

  Asian Syringa species—notably S. pinnatifolia—are documented in traditional Chinese medicine for lung disease. The broader Syringa genus is documented for bronchial and respiratory conditions including cough, bronchitis, and asthma in both Asian and European traditions.

• lilyTraditional

  Lily bulb's primary pharmacopeial indication is the Lung organ system: moistening the lungs, clearing lung heat, and relieving cough and hemoptysis. It is used in three official Chinese Pharmacopoeia species. Anti-inflammatory activity in airway models and antitussive saponin activity provide pharmacological support. Lanzhou lily polysaccharides protect the spleen and lung in preclinical models.

• marjoramTraditional

  Marjoram is traditionally used for bronchial and lung conditions including coughs, bronchitis, and chest congestion across multiple folk medicine traditions. Its expectorant classification and antispasmodic properties are relevant to lung function.

• marshmallowTraditional

  Marshmallow (Althaea officinalis) root contains mucilage (pectin-rich polysaccharides) that soothes and protects irritated respiratory mucous membranes. Commission E and ESCOP approve marshmallow root for dry and irritating cough and inflammation of the pharyngeal mucosa. It has been used in European herbal medicine since antiquity for cough, bronchitis, and throat irritation.

• menthol oilTraditional

  Menthol inhalation has been traditionally used to relieve chest congestion and support lung comfort in respiratory illness. It suppresses cough reflex via TRPM8 activation and provides a subjective sense of easier breathing, though direct bronchodilatory or mucolytic clinical evidence is limited.

• milkweedTraditional

  The lungs are the primary organ target of milkweed's most celebrated traditional use as 'pleurisy root.' A. tuberosa was official in the US Pharmacopeia for over 80 years for pulmonary diseases. It was used for pleurisy, pneumonia, bronchitis, asthma, and consumption. No clinical evidence exists to validate efficacy for any lung condition.

• mintTraditional

  Peppermint and menthol are used traditionally and in OTC formulations for respiratory symptoms involving the lungs, including cough suppression and bronchial relief. Menthol in chest rubs (Vicks VapoRub) is standard OTC practice. Limited direct clinical evidence for pulmonary endpoints exists.

• monk fruitTraditional

  Monk fruit has centuries of documented TCM use as a lung-clearing, lung-moistening herb, used specifically for conditions involving lung heat, phlegm accumulation, and dryness of the lungs. Historical patent documents confirm it was cultivated 'for hundreds of years as a traditional Chinese remedy for coughs and congestion of the lungs.' Preclinical data on mogroside anti-inflammatory activity in alveolar macrophages provides partial mechanistic support.

• morusTraditional

  Morus alba root bark (Sang Bai Pi) and leaves (Sang Ye) are core TCM herbs for lung conditions. Sang Bai Pi clears lung heat and relieves wheezing; Sang Ye dispels Wind-Heat cough. Both are listed in the Chinese Pharmacopoeia for lung indications. Anti-inflammatory mechanisms support these traditional uses.

• mulberryTraditional

  Mulberry leaf and root bark are among TCM's principal lung-affinity herbs, formally listed in the Chinese Pharmacopoeia for cough, wheezing, and respiratory infection. Mulberry leaf treats early lung infection and dry cough; root bark treats deeper bronchial conditions. Antibacterial and anti-inflammatory properties support traditional use.

• mustardTraditional

  Mustard's effect on the lungs encompasses the mucolytic/expectorant action of AITC volatiles, rubefacient chest plaster vasodilation improving lung circulation, and antimicrobial volatile oil excretion via pulmonary routes. These mechanisms underpin centuries of documented use for lung conditions from bronchitis to pneumonia.

• myrobalanTraditional

  TC is described in Ayurvedic tradition as supporting lung function and is specifically used for asthma, chronic cough, and dyspnea. It is among the organ systems listed in classical texts as benefiting from TC, with preliminary preclinical support for IgE-dependent lung conditions.

• myrrhTraditional

  Myrrh is used in traditional medicine specifically for lung congestion, bronchial conditions, and chest infections, functioning as an expectorant and anti-inflammatory. TCM specifically lists lung congestion as a medicinal use. Essential oil inhalation and chest rub preparations are described.

• neem treeTraditional

  Neem preparations are used in traditional South Asian medicine for lung and respiratory conditions including asthma and bronchitis. Leukotriene inhibition (via LOX pathway) is mechanistically relevant to airway inflammation. Human clinical trials for lung-specific outcomes with neem are absent.

• ophiopogonTraditional

  Moistening the lungs is a primary TCM action of Ophiopogon japonicus, used for dry cough, lung yin deficiency, and respiratory dryness conditions. This is one of its oldest and most consistently documented traditional indications across classical texts and modern ethnomedicinal sources.

• ophiopogon rootTraditional

  The lungs are one of the three principal meridian targets of ophiopogon root in TCM, Kampo, and the 2015 Chinese Pharmacopoeia. 'Moistening the lungs' is listed as a primary action, and the herb has been used specifically for pulmonary conditions for over two thousand years. Preclinical anti-inflammatory activity supports this traditional relationship.

• orangeTraditional

  Orange has traditional use across Chinese, Ayurvedic, and European medicine for lung conditions including cough, bronchitis, asthma, and respiratory congestion. Vitamin C from orange provides scientifically supported mucosal immunity relevant to lung health. Orange essential oil compounds have proposed mucolytic actions on bronchial secretions.

• oreganoTraditional

  Oregano has extensive traditional use for lung conditions including bronchitis, asthma, coughs, and bronchopulmonary infections across multiple global traditional medicine systems. Antimicrobial activity against respiratory pathogens and expectorant properties provide mechanistic support. No human clinical trials specifically for lung conditions have been published for oregano.

• oriental arborvitaeTraditional

  The lungs are the primary organ target for P. orientalis leaf preparations in TCM, with the plant officially listed in the Chinese Pharmacopoeia for lung-related conditions including chronic bronchitis, bronchiectasis, asthma, cough, and excessive mucus. These indications span over 1,000 years of recorded use.

• paederia foetidaTraditional

  P. foetida is used in traditional medicine for lung-related complaints including pneumonia-like conditions, bronchitis, and chest pain. Roots are used for pain in the chest and liver in Bangladeshi folk medicine. Steam inhalation is the traditional delivery method for respiratory/lung complaints.

• peachTraditional

  Peach kernel (Tao Ren) enters the Lung channel in TCM and is classified as antitussive and antiasthmatic. Peach leaves are expectorant. TCM documents peach kernel for lung abscesses and respiratory conditions. All evidence is traditional.

• pearTraditional

  Pear is the primary lung-associated food in TCM, documented across centuries as a remedy for lung heat, dryness, and irritation. Modern evidence shows pear polyphenols have lung-protective antioxidant properties in vitro. A clinical trial in COPD patients with heated pear juice did not demonstrate significant improvement in lung function outcomes.

• pennycressTraditional

  Tibetan medicine specifically used T. arvense seeds for conditions involving pus in the lungs and respiratory mucus. The plant is classified as an expectorant and diaphoretic in Chinese and European traditions, both of which relate to pulmonary function. Seeds have been used in chest plasters for lung congestion.

• plantainTraditional

  Plantago species have been used for lung conditions (asthma, emphysema, bronchitis) in traditional medicine globally. Preclinical studies in asthmatic rats show reduced lung histopathology with P. major extract. In vitro, P. lanceolata extract reduces inflammation in bronchial epithelial cells. Commission E recognizes P. lanceolata for respiratory catarrhs.

• polygalaTraditional

  The lungs are a primary organ target of P. tenuifolia according to the Chinese Pharmacopoeia, which assigns it to the Lung meridian. Traditional use for phlegm, cough, bronchitis, asthma, and whooping cough is extensively documented. Preclinical studies confirm antitussive and anti-inflammatory lung activity.

• polygala rootTraditional

  The Lung is formally listed as a target meridian of Polygala root in the Chinese Pharmacopoeia. The root is used in expectorant and anti-asthmatic formulations, with preclinical studies showing anti-inflammatory effects protecting lung tissue and reducing airway inflammation.

• poppyTraditional

  Poppy preparations have traditional use for lung-related conditions including bronchitis, pleurisy, and asthma, documented in TCM-influenced, Ayurvedic, and European folk traditions. Codeine's pharmaceutically established antitussive effect on the lung cough reflex provides partial scientific grounding.

• prickly pear cactusTraditional

  Traditional use of prickly pear for bronchial asthma, dyspnea, and whooping cough is documented in Korean, sub-Saharan, and Latin American folk medicine. Anti-inflammatory mechanisms are mechanistically relevant to airway inflammation. No clinical respiratory trials have been conducted.

• pterocarpus marsupiumTraditional

  Traditional Ayurvedic use of P. marsupium for lung-related conditions (asthma, bronchitis, cough) is documented in peer-reviewed ethnobotanical sources. No lung-specific preclinical or clinical studies have been identified.

• punarnavaTraditional

  Punarnava is listed in Ayurvedic texts for cough, asthma, and breathing disorders with expectorant and anti-histaminic properties. Preclinical data show protection against histamine-induced dyspnea in animals. Traditional use for respiratory complaints including asthma, bronchitis, and tuberculosis is documented in classical texts and ethnobotanical surveys.

• red cloverTraditional

  Red clover has a well-documented traditional use specifically targeting the lungs as an expectorant and antitussive herb, used for whooping cough, bronchitis, asthma, and mucus clearance. Multiple authoritative herbal references and ethnobotanical traditions confirm this lung-focused use. No clinical trial evidence for lung-specific endpoints exists.

• red rootTraditional

  The lungs are a traditional target of red root as an expectorant and antispasmodic herb, documented in Native American traditions (pneumonia, chronic lung complaints) and Eclectic medicine. Modern herbalists use it for pulmonary mucus congestion and bronchospasm. No clinical pulmonary function trials exist.

• schisandraTraditional

  Schisandra is a primary TCM herb for the lung meridian, used to astringe dispersing lung qi, relieve chronic cough, and moisten dry lungs. The Shennong Bencao Jing records it for 'constricting lung qi and stopping cough.' MSKCC confirms traditional use for lung symptoms but notes no clinical trials have been conducted to validate these uses.

• schisandrinsTraditional

  TCM classical pharmacopeias document Schisandra as entering the lung meridian and specifically 'constraining lung qi' to treat chronic cough and wheezing. This is among the most historically consistent documented uses, referenced in multiple TCM sources and the MSKCC monograph.

• skullcapTraditional

  S. baicalensis has 2,000-year TCM use for lung conditions including pneumonia, acute pulmonary infection, cough, and respiratory infection. Baicalin attenuates NF-κB-driven lung inflammation in cigarette smoke models. Contemporary Chinese clinical research uses S. baicalensis for 'acute pulmonary infection.'

• slippery elmTraditional

  Slippery Elm (Ulmus rubra) inner bark contains mucilage as its primary active constituent, acting as a potent demulcent and emollient for inflamed mucous membranes throughout the respiratory tract. It has been used by Native Americans and Western herbalists for cough, sore throat, and bronchitis. IntechOpen (2024) and multiple herbal pharmacopeias document its calming and restorative qualities for the respiratory system.

• slippery elm barkTraditional

  Slippery elm bark (inner bark of Ulmus rubra) contains mucilage that forms a soothing gel for inflamed respiratory mucous membranes. Native Americans and Eclectic physicians used it extensively for cough, bronchitis, and sore throat. FDA classifies it as a safe and effective OTC demulcent for sore throat. Commission E and USP document its demulcent properties.

• solomon's sealTraditional

  The lungs are a primary target organ of Solomon's seal in TCM, where P. odoratum is listed in the Chinese Pharmacopoeia for nourishing lung yin and treating dry cough. The herb is used across TCM, Ayurvedic, and Western herbal traditions as a demulcent and tonic for the pulmonary system.

• spruceTraditional

  Multiple spruce species are documented as 'pectoral' (lung-strengthening) in traditional medicine across North America and Europe. Pitch, needle infusions, and inner bark were all used internally for lung congestion, tuberculosis, and respiratory complaints. Resin chest rubs and steam inhalation of needle oil supplement internal preparations.

• stillingiaTraditional

  Stillingia was used in traditional medicine for lung conditions including chronic bronchitis, lung disease, and coughs. Eclectic physicians prescribed it for 'torpid lungs' and as an expectorant. Traditional use for lung and skin diseases is documented in southern US ethnobotany. No clinical evidence exists.

• sunflowerTraditional

  Sunflower seeds are documented in classical herbal medicine as a treatment for pulmonary affections, with expectorant and bronchial-clearing properties. Flower tea has been traditionally used for lung diseases. These uses are consistently recorded across historical herbal monographs and ethnomedicine sources.

• sweet flagTraditional

  A. calamus has traditional use for pulmonary and lung conditions including asthma, bronchitis, and respiratory infections across multiple systems. Preclinical bronchodilatory and anti-inflammatory evidence supports pulmonary relevance. Traditional classification as an expectorant positions it specifically for lung mucus conditions.

• swertiaTraditional

  Swertia chirayita is documented in Ayurvedic and traditional Himalayan medicine for lung-related conditions including asthma, cough, and bronchial ailments. Airways modulatory activity is noted in pharmacological literature. No peer-reviewed experimental studies specifically on lung tissue or human pulmonary trials have been conducted.

• tinospora cordifoliaTraditional

  T. cordifolia is traditionally described in Ayurveda for cough, asthma, and respiratory diseases. Its anti-inflammatory and anti-allergic properties support pulmonary health. Its use in Septilin for bronchitis provides indirect clinical context.

• trichosanthesTraditional

  The lung is the primary organ system attributed to Trichosanthes in TCM, which classifies the fruit, peel, and root as clearing lung heat, transforming lung phlegm, and moistening lung dryness. Both the Chinese Pharmacopoeia and major TCM references document lung abscess and pulmonary heart disease as direct indications. A 2025 murine asthma study provides preclinical evidence for lung airway anti-inflammatory effects.

• wood betonyTraditional

  Wood betony has documented traditional use for lung conditions including congestion, asthma, bronchitis, and cough. Gerard's Herball lists clearing of the lungs. It is classified as an expectorant in herbal pharmacopoeias.

• xanthium (cockleburs)Traditional

  Xanthatin from X. strumarium demonstrated anti-inflammatory activity in asthmatic mouse lung models via inhibition of STAT3 and NF-κB pathways. Chronic bronchitis is listed as a traditional TCM indication. Antitussive properties are documented across multiple ethnomedicinal traditions.